To assess the inflammatory status and anti-tumor capacity in the TME, the presence of anti-tumor CD8 + T cells, immunosuppressive CD163 + macrophages, and NK cells, critical for the ADCC-enhanced function of nadunolimab, were analyzed in the screening biopsies using immunohistochemistry. Here, CD163 is linked to neoplasm.